CIAM
ARCT icon

Caitong International Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Caitong International Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$457 Sell
68
-955
-93% -$7.53K ﹤0.01% 1759
2026
Q1 		$7.9K Buy
+1,023
New +$7.46K ﹤0.01% 1101
2025
Q3 		– Sell
-158
Closed -$2.06K – 1935
2025
Q2 		$2.06K Buy
+158
New +$1.87K ﹤0.01% 1375
2025
Q1 		– Sell
-28
Closed -$475 – 2158
2024
Q4 		$475 Buy
+28
New +$527 ﹤0.01% 1478

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Caitong International Asset Management's ARCT Position: Q2 2026 in Review

Caitong International Asset Management reduced its Arcturus Therapeutics (ARCT) stake by 93% in Q2 2026, selling an estimated $7.53K and leaving 68 shares worth $457. The position accounts for ﹤0.01% of the portfolio, ranked #1759.

Caitong International Asset Management first reported a position in ARCT in Q4 2024 and has held it in 4 quarters since. The position peaked at $7.9K in Q1 2026. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Caitong International Asset Management held 68 shares of Arcturus Therapeutics worth $457 as of Q2 2026.
  • Caitong International Asset Management sold 955 Arcturus Therapeutics shares in Q2 2026, an estimated $7.53K.
  • Arcturus Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1759 holding.
  • Caitong International Asset Management first reported a position in Arcturus Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Caitong International Asset Management's Arcturus Therapeutics position peaked at $7.9K in Q1 2026.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.